* Not included in multivariable analysis (not evaluable for some
histological subtypes)
Abbreviations: PAZ Cmin at D15: pazopanib Cmin at day 15
;PS : Performance Status; BMI : Body Mass Index ; NLR :
Neutrophil-Lymphocytes Ratio.
Overall survival in STS cohort
The median OS in the STS cohort was 13.9 months (95% CI 11.4-20.1).
Over the whole duration of follow-up, patients with PAZ
Cmin > 27 mg/L at D15 tended to have a
longer OS than other patients: 17.7 (12.0-27.6) vs 11.4 months
(7.1-18.8) (log-rank p=0.07) (Figure 2). In multivariate analysis, only
ECOG PS ≥ 2 was identified as an independent risk factor for OS (HR 2.31
[1.26-4.23], p=0.007) (table3).